The Oncotype DX® portfolio includes tests for breast, colon, and prostate cancer and have helped more than 1 million patients make more informed treatment choices.1 Oncotype DX Breast Recurrence Score® test delivers critical genomic information to help guide treatment decisions that no other genomic test or risk assessment method provides.2,3
Reason # 1: Why genomic testing? Why not genetic?
Genetic tests help people understand their risk for getting cancer. Genomic tests help guide people who have been diagnosed with cancer choose an appropriate treatment plan.
Reason #2: Only the Oncotype DX Breast Recurrence Score test has predictive and prognostic results you can count on for your early-stage invasive breast cancer patients4-7
*Predicts the benefit of adding chemotherapy to endocrine therapy.
†Node-negative and postmenopausal, HR positive, HER2 negative breast cancer.
‡Early-stage invasive HR positive, HER2 negative breast cancer.
Reason #3: Breast Recurrence Score test vs traditional assessment methods
The Breast Recurrence Score test provides strong and consistent information beyond traditional clinical and pathologic features in patient subgroups. Traditionally, breast cancer treatment was based only on clinical-pathologic factors, which provide risk estimates for a patient population. The Breast Recurrence Score test is both prognostic and predictive, providing individualized information about the estimated risk of distant recurrence and benefit of adjuvant chemotherapy that goes beyond traditional assessment menthods.4-7,27,28
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V 2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed May 2, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
ASCO and ESMO are trademarks of the American Society of Clinical Oncology. AJCC is a trademark of the American College of Surgeons. NCCN, ASCO, ESMO, St. Gallen, NICE, AGO and AJCC do not endorse any product or therapy.